Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study.
Park LK, Lim KH, Volkman J, Abdiannia M, Johnston H, Nigogosyan Z, Siegel MJ, McGill JB, McKee AM, Salam M, Zhang RM, Ma D, Popuri K, Chow VTY, Beg MF, Hawkins WG, Peterson LR, Ippolito JE. Park LK, et al. Among authors: hawkins wg. Cancer Metab. 2023 May 18;11(1):6. doi: 10.1186/s40170-023-00306-2. Cancer Metab. 2023. PMID: 37202813 Free PMC article.
A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Sanford DE, Porembka MR, Panni RZ, Mitchem JB, Belt BA, Plambeck-Suess SM, Lin G, Denardo DG, Fields RC, Hawkins WG, Strasberg SM, Lockhart AC, Wang-Gillam A, Goedegebuure SP, Linehan DC. Sanford DE, et al. Among authors: hawkins wg. J Cancer Ther. 2013 May;4(3):797-803. doi: 10.4236/jct.2013.43096. J Cancer Ther. 2013. PMID: 24089656 Free PMC article.
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, DeNardo DG, Goedegebuure SP, Linehan DC. Nywening TM, et al. Among authors: hawkins wg. Lancet Oncol. 2016 May;17(5):651-62. doi: 10.1016/S1470-2045(16)00078-4. Epub 2016 Apr 4. Lancet Oncol. 2016. PMID: 27055731 Free PMC article. Clinical Trial.
Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study.
Brauer DG, Strand MS, Sanford DE, Kushnir VM, Lim KH, Mullady DK, Tan BR Jr, Wang-Gillam A, Morton AE, Ruzinova MB, Parikh PJ, Narra VR, Fowler KJ, Doyle MB, Chapman WC, Strasberg SS, Hawkins WG, Fields RC. Brauer DG, et al. Among authors: hawkins wg. HPB (Oxford). 2017 Feb;19(2):133-139. doi: 10.1016/j.hpb.2016.11.002. Epub 2016 Dec 1. HPB (Oxford). 2017. PMID: 27916436 Free PMC article.
MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial.
Kim H, Olsen JR, Green OL, Chin RI, Hawkins WG, Fields RC, Hammill C, Doyle MB, Chapman W, Suresh R, Tan B, Pedersen K, Jansen B, DeWees TA, Lu E, Henke LE, Badiyan S, Parikh PJ, Roach MC, Wang-Gillam A, Lim KH. Kim H, et al. Among authors: hawkins wg. Int J Radiat Oncol Biol Phys. 2023 Jan 1;115(1):214-223. doi: 10.1016/j.ijrobp.2022.07.015. Epub 2022 Jul 22. Int J Radiat Oncol Biol Phys. 2023. PMID: 35878713 Clinical Trial.
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.
Wang-Gillam A, Lim KH, McWilliams R, Suresh R, Lockhart AC, Brown A, Breden M, Belle JI, Herndon J, Bogner SJ, Pedersen K, Tan B, Boice N, Acharya A, Abdiannia M, Gao F, Yoon HH, Zhu M, Trikalinos NA, Ratner L, Aranha O, Hawkins WG, Herzog BH, DeNardo DG. Wang-Gillam A, et al. Among authors: hawkins wg. Clin Cancer Res. 2022 Dec 15;28(24):5254-5262. doi: 10.1158/1078-0432.CCR-22-0308. Clin Cancer Res. 2022. PMID: 36228156 Free PMC article. Clinical Trial.
Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology.
Panni UY, Chen MY, Zhang F, Cullinan DR, Li L, James CA, Zhang X, Rogers S, Alarcon A, Baer JM, Zhang D, Gao F, Miller CA, Gong Q, Lim KH, DeNardo DG, Goedegebuure SP, Gillanders WE, Hawkins WG. Panni UY, et al. Among authors: hawkins wg. Cancer Immunol Immunother. 2023 Aug;72(8):2813-2827. doi: 10.1007/s00262-023-03463-x. Epub 2023 May 13. Cancer Immunol Immunother. 2023. PMID: 37179276 Free PMC article.
ASO Visual Abstract: Plasma Ceramide C24:0/C16:0 Ratio is Associated with Improved Survival in Patients with Pancreatic Ductal Adenocarcinoma.
Mitchell JD, Panni U, Fergestrom N, Toriola AT, Nywening TM, Goedegebuure SP, Jiang X, Mudd JL, Cao Y, Ippolito J, Fields RC, Hawkins WG, Peterson LR. Mitchell JD, et al. Among authors: hawkins wg. Ann Surg Oncol. 2024 Oct 25. doi: 10.1245/s10434-024-16375-6. Online ahead of print. Ann Surg Oncol. 2024. PMID: 39453587 No abstract available.
228 results